Melasma Pharmaceuticals is spin off company of Micar Innovation, registered in Sofia, Bulgaria. Under terms of the agreement, Micar Innovation grants Melasma Pharmaceuticals (Sofia - Bulgaria) an exclusive option to license and develop MIC8411 drugs targeting Melasma disease. Melasma Pharmaceuticals capital is in the hands of Micar Innovation driven by impact and provide value to our future investors.
Melasma Pharmaceuticals aim
Melasma Pharmaceuticals (spin off company of Micar Innovation) is specialized in the discovery, development and commercialization of the small molecule drugs and transforming the treatment of Melasma by advancing one of the largest, exclusively focused clinical pipelines of novel therapies. By using structure based in silico drug design & AI (Micar21 platform) we constructed the best Melasma drug candidate fast & validated.
We aim to bridge the safety and efficacy gaps in current approaches to Melasma management. The company is focused on the development of the safe next-generation Melasma killer for the patients suffering from Melasma. Melasma Pharmaceuticals lead drug candidate, MIC8411, is currently in the phase preclinical for the treatment of Melasma.
Melasma Pharmaceuticals Mission
Melasma is a growing problem – not only in terms of the significant number of people that are impacted and the burden this places on our healthcare system. Our mission is to relieve the suffering associated with Melasma by developing treatments that address the safety and efficacy gaps in the current treatment paradigm.
Our broad pipeline represents our mission to tackle the problem of Melasma head on by developing treatments that act at new or emerging pharmacological targets and delivering them in ways that best address the particular type of Melasma.